Sionna Therapeutics, Inc. Common Stock Total Liabilities
Sionna Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has total liabilities worth $19.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sionna Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sionna Therapeutics, Inc. Common Stock (2022–2025)
Total liabilities of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Sionna Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Sionna Therapeutics, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Sionna Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
Israel | ILA1.25 Billion |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
Switzerland | CHF120.20 Million |
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
USA | $25.69 Million |
|
InfoBeans Technologies Limited
NSE:INFOBEAN
|
India | Rs-4.14 Billion |
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
Germany | €1.09 Billion |
|
Dae Young Pkg
KO:014160
|
Korea | ₩72.47 Billion |
|
Omiris AG
F:HBD1
|
Germany | €1.83 Million |
|
American Battery Technology Company Common Stock
NASDAQ:ABAT
|
USA | $4.36 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Sionna Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Sionna Therapeutics, Inc. Common Stock's balance sheet.
Liquidity & Leverage Metrics
Sionna Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Sionna Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sionna Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.12 Million | -94.53% |
| 2024-12-31 | $349.46 Million | +109.48% |
| 2023-12-31 | $166.83 Million | +6.06% |
| 2022-12-31 | $157.29 Million | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more